Bioproduction of viral vectors: challenges, innovations and market prospects
Viral vectors are essential therapeutic tools for gene therapy and certain vaccines. The growing number of cell and gene therapy products on the market means that the production of viral vectors is an increasingly strategic sector.
Biomanufacturing of biological drugs: strategic issues and challenges
Biomanufacturing, or the manufacturing phase of innovative biological medicines, is a rapidly expanding field that is essential for meeting modern healthcare needs and represents a major strategic challenge. Faced with growing dependence on imports and increasing international competition, there are many technological and industrial challenges to developing this sector. In France, major efforts are being made, notably through the France 2030 plan, to ensure pharmaceutical sovereignty and meet future medical needs. This article explores the challenges and opportunities presented by biomanufacturing.
The beginnings of cell culture
Cell culture is the cornerstone of biomedical research and biotechnology innovation. Although the bioproduction of biomedicines in bioreactors is now the norm, and the use of organoids and “organ-on-a-chip” (OoC) is growing, the beginnings of in vitro cell culture were more modest.
Advanced therapy medicinal products: from the lab to the patient’s bed
Advanced therapy medicinal products (ATMPs) explore new therapeutic approaches based on genome modification, manipulation of patient or healthy donor cells and other innovative methods, representing a major transition from traditional medicine to more personalized and targeted medicine.
The history of biologics: from discovery to therapeutic revolution
Biopharmaceuticals, or biotherapies, are becoming increasingly important on the market, and offer immense hope for the treatment of many diseases. From the first discoveries of vaccines to the recent development of cell and gene therapies and regenerative medicine, looking back at biologics’ history lets us have a better understanding of the revolution that they provoked in the pharmaceutical industry and in modern medicine .
Monoclonal antibodies: the stars of therapeutic proteins
Hybridoma technology for the production of monoclonal antibodies (mAbs), awarded the Nobel Prize for Medicine in 1984, revolutionized serotherapy, which previously used patient serum containing mixtures of antibodies. More targeted and therefore more effective, mAbs offer innovative perspectives in the treatment of various diseases, and have become an essential therapeutic strategy in our pharmaceutical arsenal.
